Stockscreener 앱 받기
23.38
2.54%
-0.61
전일 마감가:
$23.99
열려 있는:
$24.675
하루 거래량:
88,967
Relative Volume:
0.62
시가총액:
$343.18M
수익:
-
순이익/손실:
$-19.48M
주가수익비율:
-15.97
EPS:
-1.4641
순현금흐름:
$-8.59M
1주 성능:
+1.52%
1개월 성능:
-13.02%
6개월 성능:
+88.70%
1년 성능:
+162.11%
1일 변동 폭
$22.60
$24.90
1주일 범위
$22.60
$25.50
52주 변동 폭
$7.78
$34.10
그리니치 Stock (GLSI) Company Profile
명칭
Greenwich Lifesciences Inc
전화
203-434-3290
주소
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
23.38 | 343.18M | 0 | -19.48M | -8.59M | -1.4641 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
그리니치 Stock (GLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 개시 | Noble Capital Markets | Outperform |
| 2021-09-01 | 개시 | H.C. Wainwright | Buy |
그리니치 주식(GLSI)의 최신 뉴스
Greenwich Lifesciences Inc (GLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Greenwich Lifesciences Inc (GLSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Greenwich Lifesciences Inc (GLSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Greenwich Lifesciences Inc (GLSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Greenwich Lifesciences Inc (GLSI) Institutional Confidence - TradingKey
Greenwich Lifesciences Inc (GLSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Greenwich Lifesciences Inc (GLSI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Greenwich Lifesciences Inc (GLSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Greenwich Lifesciences Inc (GLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GLSI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GLSI Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D Investment - newsline.com
Technical Reactions to GLSI Trends in Macro Strategies - Stock Traders Daily
Greenwich LifeSciences (GLSI) Rises 4.47% as Shares Approach $25 ResistanceTechnical Analysis Picks - newsline.com
Greenwich LifeSciences, Inc. Q1 2026 Quarterly Report: Financials, Risk Factors, and Disclosure Highlights - Minichart
Trading the Move, Not the Narrative: (GLSI) Edition - Stock Traders Daily
Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Greenwich LifeSciences (GLSI) loss widens as ATM equity raises fund trials - Stock Titan
What’s Driving GLSI Stock Today? - Stocktwits
GLSI Q4 2025 Earnings: Wider-than-Expected Loss as No Revenue ReportedReturn On Assets - newsline.com
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
Greenwich LifeSciences, Inc. 2024 Annual Report: Breast Cancer Immunotherapy Pipeline, Clinical Trials, and Regulatory Risks - minichart.com.sg
GREENWICH LIFESCIENCES ($GLSI) Releases Q4 2025 Earnings - Quiver Quantitative
Greenwich LifeSciences FY 2025: Net loss $19.4M, No revenue — 10-K Summary - TradingView
Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Greenwich LifeSciences delays 10-K filing, cites audit coordination By Investing.com - Investing.com Nigeria
Greenwich LifeSciences presents immune response data at ASCO - Investing.com
Greenwich LifeSciences presents immune response data at ASCO By Investing.com - Investing.com South Africa
Breast cancer trial: GLSI-100 shots spark injection-site reactions over time - Stock Titan
GLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer Trial - TradingView
Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval - Moomoo
Greenwich Lifesciences Provides Update Regarding Form 10-K Filing - TradingView
Greenwich LifeSciences updates on Form 10-K filing progress - Traders Union
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing - The Manila Times
Greenwich LifeSciences, Inc. Provides Update on 2025 Form 10-K Filing and Phase III Clinical Trial Progress - Quiver Quantitative
Greenwich LifeSciences delays 10-K filing, cites audit coordination - Investing.com
Breast cancer trial firm details audit delay, $10.5M cash - Stock Titan
Auddia’s Discovr Radio Forms AI-Driven Partnership With Beatcave to Expand Independent Artist Discovery Across Canada - Weekly Voice
Greenwich LifeSciences, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Greenwich LifeSciences (GLSI) Drops Nearly 10%: Key Support and Resistance Levels in FocusInsider Selling Alerts - The Legal Advocate
GLSI Q3 2025 Earnings: Narrower-than-Expected Loss as Biotech Advances Clinical PipelineLow Growth Earnings - newsline.com
Greenwich LifeSciences (GLSI) Slips Marginally as Stock Holds Above Key SupportIchimoku Kumo Twist - The Legal Advocate
Greenwich LifeSciences Inc. (GLSI) Q3 2025 Earnings: Narrowed Loss Highlights Progress in Immunotherapy DevelopmentQuarterly Earnings - newsline.com
Greenwich LifeSciences (GLSI) Surges 7% as Biotech Momentum BuildsHigh Dividend Factor - newsline.com
GLSI Technical Analysis | Trend, Signals & Chart Patterns | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
Greenwich LifeSciences Inc. (GLSI) Edges Higher as Shares Approach Key ResistanceDouble EMA - The Legal Advocate
(GLSI) Volatility Zones as Tactical Triggers - Stock Traders Daily
Greenwich LifeSciences receives Nasdaq notice regarding late Form 10-Q filing - MSN
Greenwich LifeSciences receives Nasdaq noncompliance notice By Investing.com - Investing.com Nigeria
Greenwich LifeSciences: Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing - Moomoo
Greenwich LifeSciences receives Nasdaq noncompliance notice - Investing.com
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Weekly Voice
그리니치 (GLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):